Health Care Innovation
Commentary
The Inflation Reduction Act Kills the Golden Goose That Could End Cancer
President Joe Biden recently relaunched his Cancer Moonshot initiative. His passion for ending cancer is commendable. Unfortunately, the policies he has enacted will undermine his quest. The Cancer Moonshot aims to reduce the death rate from cancer by 50 percent over the next 25 years by pouring money into cancer research and improving coordination ...
Commentary
Pay No Attention To Biden’s Biotech Bluster
Speaking in Boston earlier this month, President Biden insisted that the United States can “end cancer as we know it and even cure cancers once and for all.” His “Cancer Moonshot” aims to do just that. Among its many lofty goals, it seeks to halve cancer deaths in the next 25 years. ...
Commentary
What’s at fault for lower life expectancy? Health care has less influence than individual choices.
New life expectancy data from the Centers for Disease Control and Prevention seems to indicate that things are getting only worse. Between 2020 and 2021, American life expectancy decreased 0.9 years. That follows a drop of 1.8 years in 2020.
Commentary
Violating Manufacturer’s Property Rights Does Not Promote Healthy Competition
Too often, regulations undermine the competitive process in the name of promoting competition. The ill-conceived Right to Repair legislation exemplify the problems and risks. Under the pretense of promoting competition, states as diverse as Texas and California, Arkansas and Hawaii have all considered bills that would violate medical device companies’ intellectual property rights. While many have been defeated, ...
Drug Pricing
Wayne Winegarden Discusses Prescription Drug Prices on Scripps National News
Watch PRI’s Wayne Winegarden, director of our Center for Medical Economics and Innovation, discuss efforts by the Federal Trade Commission to considering ordering large pharmacy benefits managers to study the competitive impact of contractual provisions, reimbursement adjustments, and other practices affecting drug prices on Scripps National News.
Commentary
The FDA Needs Reform – Biden’s Nominee Is Not the Person to Do It
When President Joe Biden nominated former Obama-era Food and Drug Administration Commissioner Dr. Robert Califf to return to his old post, he made what was widely seen as a safe, if uninspired, choice. He easily sailed through a Dec. 14 Senate committee hearing to vet him. “[Califf] gushed about his love of high-quality ...
Health Care
Wayne Winegarden Discusses 340B Hospital Study on AM 1590 in Boone, IA
Listen to Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent 340B hospital study on AM 1590, KWBG Radio in Boone, IA. https://www.pacificresearch.org/wp-content/uploads/2022/02/Wayne-Winegarden-PRI-340B-Study-012522.mp3
Drug Prices
NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients
Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics ...
Commentary
Drug discount program padding hospital profits
Improving vulnerable populations’ access to medicines is clearly important. But something is amiss when a program that is supposed to improve access to healthcare has turned into a cash cow for hospitals. Yet, that is what has happened to the obscure 340B drug discount program. Too many hospitals across Massachusetts ...
Commentary
Democrats Eye Canada’s Failed Healthcare System – Why?
Democrats in Congress are working to resurrect the Build Back Better Act, their massive social spending proposal that stalled in the Senate last month. To be certain, there’s plenty of disagreement across the party’s moderate and progressive wings. Yet, they’re largely aligned on healthcare. Indeed, Democrats are determined to increase the number ...
The Inflation Reduction Act Kills the Golden Goose That Could End Cancer
President Joe Biden recently relaunched his Cancer Moonshot initiative. His passion for ending cancer is commendable. Unfortunately, the policies he has enacted will undermine his quest. The Cancer Moonshot aims to reduce the death rate from cancer by 50 percent over the next 25 years by pouring money into cancer research and improving coordination ...
Pay No Attention To Biden’s Biotech Bluster
Speaking in Boston earlier this month, President Biden insisted that the United States can “end cancer as we know it and even cure cancers once and for all.” His “Cancer Moonshot” aims to do just that. Among its many lofty goals, it seeks to halve cancer deaths in the next 25 years. ...
What’s at fault for lower life expectancy? Health care has less influence than individual choices.
New life expectancy data from the Centers for Disease Control and Prevention seems to indicate that things are getting only worse. Between 2020 and 2021, American life expectancy decreased 0.9 years. That follows a drop of 1.8 years in 2020.
Violating Manufacturer’s Property Rights Does Not Promote Healthy Competition
Too often, regulations undermine the competitive process in the name of promoting competition. The ill-conceived Right to Repair legislation exemplify the problems and risks. Under the pretense of promoting competition, states as diverse as Texas and California, Arkansas and Hawaii have all considered bills that would violate medical device companies’ intellectual property rights. While many have been defeated, ...
Wayne Winegarden Discusses Prescription Drug Prices on Scripps National News
Watch PRI’s Wayne Winegarden, director of our Center for Medical Economics and Innovation, discuss efforts by the Federal Trade Commission to considering ordering large pharmacy benefits managers to study the competitive impact of contractual provisions, reimbursement adjustments, and other practices affecting drug prices on Scripps National News.
The FDA Needs Reform – Biden’s Nominee Is Not the Person to Do It
When President Joe Biden nominated former Obama-era Food and Drug Administration Commissioner Dr. Robert Califf to return to his old post, he made what was widely seen as a safe, if uninspired, choice. He easily sailed through a Dec. 14 Senate committee hearing to vet him. “[Califf] gushed about his love of high-quality ...
Wayne Winegarden Discusses 340B Hospital Study on AM 1590 in Boone, IA
Listen to Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent 340B hospital study on AM 1590, KWBG Radio in Boone, IA. https://www.pacificresearch.org/wp-content/uploads/2022/02/Wayne-Winegarden-PRI-340B-Study-012522.mp3
NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients
Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics ...
Drug discount program padding hospital profits
Improving vulnerable populations’ access to medicines is clearly important. But something is amiss when a program that is supposed to improve access to healthcare has turned into a cash cow for hospitals. Yet, that is what has happened to the obscure 340B drug discount program. Too many hospitals across Massachusetts ...
Democrats Eye Canada’s Failed Healthcare System – Why?
Democrats in Congress are working to resurrect the Build Back Better Act, their massive social spending proposal that stalled in the Senate last month. To be certain, there’s plenty of disagreement across the party’s moderate and progressive wings. Yet, they’re largely aligned on healthcare. Indeed, Democrats are determined to increase the number ...
